Author: Tom Wilemon
May. 12, 2021—The second session of the American Association for Cancer Research (AACR) Annual meeting, May 17-21, features several researchers from Vanderbilt-Ingram Cancer Center.
May. 11, 2021—The American College of Medical Genetics and Genomics (ACMG) has released important new clinical practice guidance for the surveillance and treatment of patients with a gene variant that puts them at increased risk for cancer.
Apr. 29, 2021—Lindsay Grisanti, LMSW, is the recipient of the Carolyn Edwards Social Worker of the Year Award at Vanderbilt University Medical Center.
Apr. 21, 2021—Wei Zheng, MD, PhD, MPH, Anne Potter Wilson Professor of Medicine, has been named associate director for Population Sciences Research at Vanderbilt- Ingram Cancer Center (VICC).
Apr. 15, 2021—Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.
Mar. 26, 2021—A radiation therapy device for the treatment of a rare cancer has been designed, custom built and installed at Vanderbilt-Ingram Cancer Center at Maury Regional Spring Hill, offering patients from Alabama, Mississippi, Georgia and southern Tennessee more convenient care.
Mar. 25, 2021—Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
Mar. 25, 2021—Researchers from Vanderbilt University Medical Center are part of a multi-institutional study that aims to improve participation in lung cancer clinical trials among Black patients from Southern states.
Mar. 18, 2021—The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
Mar. 18, 2021—Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.